Dérivés de l'isocytosine antagonistes des récepteurs H2 de l'histamine. III. Synthèse et activité biologique de la lupitidine (SK&F 93479) et de composés apparentés
Preparation and Reactions of Heteroarylmethylzinc Reagents
作者:Nadja M. Barl、Elodie Sansiaume-Dagousset、Gabriel Monzón、Andreas J. Wagner、Paul Knochel
DOI:10.1021/ol500790p
日期:2014.5.2
We report a general preparation of heteroarylmethylzinc chlorides by directzincinsertion into heteroarylmethyl chlorides, along with a facile and straightforward synthesis of these heterocyclic chloromethyl precursors. We demonstrate that heteroarylmethylzinc reagents undergo various reactions including cross-couplings, allylations, acylations, and addition reactions to aldehydes, leading to polyfunctional
Ru-catalysed C–H silylation of unprotected gramines, tryptamines and their congeners
作者:K. Devaraj、C. Sollert、C. Juds、P. J. Gates、L. T. Pilarski
DOI:10.1039/c6cc00803h
日期:——
Selective Ru-catalysed C2-H silylation of heteroarenes is presented. The transformation works with or without directing group assistance and requires no protecting groups. Gramines and tryptamines may be converted efficiently whilst...
Mannich reactiohs of aryltrialkylstannunes in aprotic solvents
作者:Mark S. Cooper、Robin A. Fairhurst、Harry Heaney、George Papageorgiou、Robert F. Wilkins
DOI:10.1016/0040-4020(89)80024-9
日期:1989.1
Aryltributyl- and aryltrimethyl-stannanes react with a range of N,N-dialkylmethylene-imonium salts to afford N,N-dialkylaminomethyl derivatives in good yields. The method can be used to obtain regloisomers that are not available using classical procedures. “In situ” reactions can also be carried out using alkoxydialkylaminomethanes (aminol ethers) and bis(dialkylamino)methanes (aminals) together with
(EN) This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula (I) as defined herein. It also provides novel compounds of formula (I), processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula (I).(FR) La présente invention concerne l'utilisation, comme inhibiteurs de thrombine, inhibiteurs de coagulation et agents destinés aux désordres de la thromboembolie, de diamines de formule I telle qu'elle est définie dans la description. L'invention concerne aussi des composés nouveaux de formule I, des procédés et des produits intermédiaires pour leur préparation, et des formulations pharmaceutiques comprenant les composés nouveaux de formule I.
Solution Structure and Chelation Properties of 2-Thienyllithium Reagents
作者:Kevin L. Jantzi、Craig L. Puckett、Ilia A. Guzei、Hans J. Reich
DOI:10.1021/jo050592+
日期:2005.9.1
The solution and chelation properties of 2-thienyllithium reagents with potential amine and ether chelating groups in the 3-position and related model systems have been investigated using low temperature Li-6, Li-7, C-13, and P-31 NMR spectroscopy, N-15-labeling, and the effect of solvent additives. In THF-ether mixtures at low temperature 3-(N,N-dimethylaminomethyl)-2-thienyllithium (4) is ca. 99% dimer (which is chelated) and 1% monomer (unchelated), whereas 3-(methoxymethyl)-2thienyllithium (5) is < 10% dimer. Compound 5 crystallizes as a THF-solvated dimer, but there is no indication that the ether side chain is chelated in solution. Both 4 and 5 form PMDTA-complexed monomers almost stoichiometrically, similar to the model compound 2, in sharp contrast to phenyl analogues, which show very different behavior. The barriers to dimer interconversion are ca. 2 kcal/mol lower and chelation is significantly weaker in the 2-thienyllithium reagents than in their phenyl analogues.